Cargando…

Fecal Microbial Composition of Ulcerative Colitis and Crohn’s Disease Patients in Remission and Subsequent Exacerbation

BACKGROUND: Limited studies have examined the intestinal microbiota composition in relation to changes in disease course of IBD over time. We aimed to study prospectively the fecal microbiota in IBD patients developing an exacerbation during follow-up. DESIGN: Fecal samples from 10 Crohn’s disease (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wills, Edgar S., Jonkers, Daisy M. A. E., Savelkoul, Paul H., Masclee, Ad A., Pierik, Marieke J., Penders, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946581/ https://www.ncbi.nlm.nih.gov/pubmed/24608638 http://dx.doi.org/10.1371/journal.pone.0090981

Ejemplares similares

The fecal microbiota as a biomarker for disease activity in Crohn’s disease
por: Tedjo, Danyta. I., et al.
Publicado: (2016)

The Effect of Sampling and Storage on the Fecal Microbiota Composition in Healthy and Diseased Subjects
por: Tedjo, Danyta I., et al.
Publicado: (2015)

Corticosteroid enhances epithelial barrier function in intestinal organoids derived from patients with Crohn’s disease
por: Xu, Pan, et al.
Publicado: (2021)

Faecal Microbiota Dynamics and their Relation to Disease Course in Crohn’s Disease
por: Galazzo, Gianluca, et al.
Publicado: (2019)

Metagenomic Profiling of Fecal-Derived Bacterial Membrane Vesicles in Crohn’s Disease Patients
por: Kameli, Nader, et al.
Publicado: (2021)

Higher Prevalence of Bacteroides fragilis in Crohn’s Disease Exacerbations and Strain-Dependent Increase of Epithelial Resistance
por: Becker, Heike E. F., et al.
Publicado: (2021)

Modulation of Intestinal Epithelial Permeability by Plasma from Patients with Crohn’s Disease in a Three-dimensional Cell Culture Model
por: Xu, Pan, et al.
Publicado: (2019)

Impact of Sleeve Gastrectomy on Fecal Microbiota in Individuals with Morbid Obesity
por: Tedjo, Danyta I., et al.
Publicado: (2023)

High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score
por: Bodelier, Alexander G. L., et al.
Publicado: (2016)

Disease Activity Patterns of Crohn’s Disease in the First Ten Years After Diagnosis in the Population-based IBD South Limburg Cohort
por: Wintjens, Dion, et al.
Publicado: (2020)

Fecal calprotectin as a noninvasive test to predict deep remission in patients with ulcerative colitis
por: Malvão, Ludimilla dos Reis, et al.
Publicado: (2021)

Fecal microbiota transplantation versus glucocorticoids for the induction of remission in mild to moderate ulcerative colitis
por: Huang, Chunlan, et al.
Publicado: (2022)

Capsulized Fecal Microbiota Transplantation Induces Remission in Patients with Ulcerative Colitis by Gut Microbial Colonization and Metabolite Regulation
por: Chen, Qiongyun, et al.
Publicado: (2023)

Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease
por: Gauss, Annika, et al.
Publicado: (2016)

Off‐label prescriptions of drugs used for the treatment of Crohn’s disease or ulcerative colitis
por: Simsek, Melek, et al.
Publicado: (2019)

Metabonomics of human fecal extracts characterize ulcerative colitis, Crohn’s disease and healthy individuals
por: Bjerrum, Jacob Tveiten, et al.
Publicado: (2014)

Fecal Filobasidium Is Associated with Clinical Remission and Endoscopic Response following Fecal Microbiota Transplantation in Mild-to-Moderate Ulcerative Colitis
por: van Thiel, Isabelle A. M., et al.
Publicado: (2022)

Inter-kingdom relationships in Crohn’s disease explored using a multi-omics approach
por: Frau, Alessandra, et al.
Publicado: (2021)

Fecal microbiota dynamics during disease activity and remission in newly diagnosed and established ulcerative colitis
por: Öhman, Lena, et al.
Publicado: (2021)

Fecal microbiota transplantation for the maintenance of remission in patients with ulcerative colitis: A randomized controlled trial
por: Lahtinen, Perttu, et al.
Publicado: (2023)

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease: Erratum
Publicado: (2016)

Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn’s disease and ulcerative colitis
por: Hashash, Jana G., et al.
Publicado: (2021)

The Role of Probiotics in Inducing and Maintaining Remission in Crohn’s Disease and Ulcerative Colitis: A Systematic Review of the Literature
por: Vakadaris, Georgios, et al.
Publicado: (2023)

The Clinical and Steroid-Free Remission of Fecal Microbiota Transplantation to Patients with Ulcerative Colitis: A Meta-Analysis
por: Lam, Wai Ching, et al.
Publicado: (2019)

The Distinguishing Bacterial Features From Active and Remission Stages of Ulcerative Colitis Revealed by Paired Fecal Metagenomes
por: Zhu, Ran, et al.
Publicado: (2022)

Fecal microbiota in pouchitis and ulcerative colitis
por: Li, Kai-Yu, et al.
Publicado: (2016)

Fecal leukocyte in the diagnosis of ulcerative colitis
por: Saraya, Takeshi, et al.
Publicado: (2013)

Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis
por: Kim, Seok-Young, et al.
Publicado: (2023)

Therapeutic Potential of Proanthocyanidins in Ulcerative Colitis in Remission
por: Głąbska, Dominika, et al.
Publicado: (2020)

Transcriptional Signatures That Define Ulcerative Colitis in Remission
por: Fenton, Christopher G, et al.
Publicado: (2020)

Does Day-to-Day Variability in Stool Consistency Link to the Fecal Microbiota Composition?
por: Vork, Lisa, et al.
Publicado: (2021)

Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trial
por: Janssen, Laura, et al.
Publicado: (2021)

The reproducibility of skeletal muscle signal intensity on routine magnetic resonance imaging in Crohn's disease
por: Spooren, Corinne E.G.M., et al.
Publicado: (2020)

Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn’s Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature
por: Smeets, Fabiënne G M, et al.
Publicado: (2019)

Crohn's disease and ulcerative colitis Surgical management
por: Wilkinson, A J
Publicado: (1996)

Mucosal Barrier in Ulcerative Colitis and Crohn's Disease
por: Dorofeyev, A. E., et al.
Publicado: (2013)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Ulcerative Colitis and Crohn's Disease: Similarities and Distinctions
por: Sawyerr, Af M, et al.
Publicado: (1994)

Review of pregnancy in Crohn’s disease and ulcerative colitis
por: Laube, Robyn, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8lnkdodreauu4bu6r9rbcj1er3